Loading...
Rising Clinical Risks Will Depress Biotech Pipeline Yet Invite Rebound
AnalystLowTarget's Fair Value
US$38.23
23.9% undervalued intrinsic discount04 Sep
US$29.08
1Y
-47.7%7D
-1.3%1Y
-47.7%7D
-1.3%You can edit this narrative until Aug 6 10:10 PM. Then, changes will post as Updates.